Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St Jude Begins Major Lead Assessment Study

This article was originally published in The Gray Sheet

You may also be interested in...



News In Brief

AdvaMed presents CEO survey to FDA. Former ArthoCare exec pleads guilty to securities fraud charges from DOJ. CMS lists teaching hospitals that qualify for inclusion in company’s physician payment sunshine disclosure requirements. More news.

Research In Brief

Data preview for Heart Rhythm Society conference in Denver this week. More research news.

Challenges With ICD Leads Are Under Control, St. Jude Tells Investors

The company was prepared for FDA’s recent warning letter, executives said on an earnings call. But the scrutiny is not over, analysts suggest.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT031982

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel